Actively Recruiting
In Vivo Cortical Excitability Modulation in Major Depressive Disorder
Led by Fundacao Champalimaud · Updated on 2025-02-26
90
Participants Needed
1
Research Sites
293 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The pathophysiology of Major Depression Disorder (MDD) is unclear, with several theories for its neurobiological mechanisms. One possible explanation is the presence of altered neuroplasticity, which can be studied by Transcranial Magnetic Stimulation (TMS). Using TMS to study these mechanisms is performed by applying electromagnetic stimuli to the motor cortex, to obtain measures of temporary cortical excitability modulation. It is known that depressed patients with higher cortical modulation are more responsive to a TMS treatment course. However, it is unknown if there are differences in cortical modulation between depressed patients and healthy subjects. Our goal is to answer this question and contribute towards clarification of the neuroplasticity mechanisms underlying MDD. Accordingly, the investigators will access cortical excitability modulation measures in both depressed patients and healthy volunteers and compare their results. The investigators will also re-assess these measures after 6 weeks of antidepressant treatment. Finally, the investigators will study the association between cortical excitability measures and cognitive processes using an innovative cognitive task.
CONDITIONS
Official Title
In Vivo Cortical Excitability Modulation in Major Depressive Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of major depressive episode or disorder as provided in the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5)
You will not qualify if you...
- Moderate to severe suicide risk
- Known personal history of bipolar disorder or psychotic disorder
- Alcohol or other substance abuse and/or dependence
- Developmental disorder
- Dementia
- Presence of uncontrolled active medical illness
- Known structural lesion of the central nervous system
- Electrical or metallic brain implants
- Cardiac implants
- Epilepsy
- Active use of medication known to cause seizures
- Pregnancy
- Breastfeeding
- History of neuropsychiatric disease for healthy control group
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Champalimaud Foundation
Lisbon, Portugal, 1400-038
Actively Recruiting
Research Team
S
Sofia Marques
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here